AInvest★★★★★3-DAY FREE
Catch pre-market movers with AI signals.
Claim Trial
Progyny up 6% on insider buys
PorAinvest
viernes, 27 de diciembre de 2024, 8:44 am ET1 min de lectura
PGNY--
One of the most significant purchases was made by Ali Motamed, the Chief Investment Officer of Invenomic Capital Management. Motamed acquired 1,760,706 shares of PGNY, worth approximately $29.5 million [2]. This transaction represented a sizable 1.62% increase in Motamed's total holdings of the company [2].
Another notable insider purchase was made by Philip Timon, the Founder and Chief Investment Officer of Owls Nest Partners. Timon sold 1,523,147 shares of PGNY but simultaneously purchased 1,523,147 new shares [2]. Although this transaction resulted in no net change to Timon's overall holdings, it demonstrated his confidence in the company's future prospects.
The hedge fund with the largest stake in PGNY is Farallon Capital, managed by Thomas Steyer. Steyer reduced his holdings by selling 931,307 shares of the company, worth around $15.6 million [2]. Despite this sale, Steyer still holds a significant 0.07% stake in PGNY [2].
Steve Cohen, the Founder and Chief Executive Officer of Point72 Asset Management, also made a notable purchase of 789,418 shares of PGNY, worth approximately $13.2 million [2]. This transaction represented a substantial 228% increase in Cohen's total holdings of the company [2].
Israel Englander, the Founder and Chief Investment Officer of Millennium Management, acquired 563,535 shares of PGNY, worth around $9.4 million [2]. This purchase represented a 6% increase in Englander's overall holdings of the company [2].
The insider buying activity at PGNY is a positive sign for the company, as it demonstrates confidence from key executives and prominent investors. With a strong focus on fertility benefits, PGNY is well-positioned to capitalize on the growing demand for healthcare services in this area [1].
References:
[1] OpenInsider. Progyny Inc. Retrieved November 15, 2024, from http://openinsider.com/PGNY
[2] Insidermonkey. Progyny Inc. Hedge Fund Trading. Retrieved November 15, 2024, from https://www.insidermonkey.com/insider-trading/company/progyny+inc/1551306/
Progyny up 6% on insider buys
Progyny Inc. (PGNY), a healthcare services company specializing in fertility benefits, experienced a notable surge of 6% in its stock price on November 14, 2024 [1]. This uptick can be attributed to a series of insider purchases made by key executives and prominent hedge funds [2].One of the most significant purchases was made by Ali Motamed, the Chief Investment Officer of Invenomic Capital Management. Motamed acquired 1,760,706 shares of PGNY, worth approximately $29.5 million [2]. This transaction represented a sizable 1.62% increase in Motamed's total holdings of the company [2].
Another notable insider purchase was made by Philip Timon, the Founder and Chief Investment Officer of Owls Nest Partners. Timon sold 1,523,147 shares of PGNY but simultaneously purchased 1,523,147 new shares [2]. Although this transaction resulted in no net change to Timon's overall holdings, it demonstrated his confidence in the company's future prospects.
The hedge fund with the largest stake in PGNY is Farallon Capital, managed by Thomas Steyer. Steyer reduced his holdings by selling 931,307 shares of the company, worth around $15.6 million [2]. Despite this sale, Steyer still holds a significant 0.07% stake in PGNY [2].
Steve Cohen, the Founder and Chief Executive Officer of Point72 Asset Management, also made a notable purchase of 789,418 shares of PGNY, worth approximately $13.2 million [2]. This transaction represented a substantial 228% increase in Cohen's total holdings of the company [2].
Israel Englander, the Founder and Chief Investment Officer of Millennium Management, acquired 563,535 shares of PGNY, worth around $9.4 million [2]. This purchase represented a 6% increase in Englander's overall holdings of the company [2].
The insider buying activity at PGNY is a positive sign for the company, as it demonstrates confidence from key executives and prominent investors. With a strong focus on fertility benefits, PGNY is well-positioned to capitalize on the growing demand for healthcare services in this area [1].
References:
[1] OpenInsider. Progyny Inc. Retrieved November 15, 2024, from http://openinsider.com/PGNY
[2] Insidermonkey. Progyny Inc. Hedge Fund Trading. Retrieved November 15, 2024, from https://www.insidermonkey.com/insider-trading/company/progyny+inc/1551306/

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema



Comentarios
Aún no hay comentarios